Molnupiravir + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease (COVID-19)
Conditions
Coronavirus Disease (COVID-19)
Trial Timeline
Aug 11, 2021 → Nov 16, 2022
NCT ID
NCT04939428About Molnupiravir + Placebo
Molnupiravir + Placebo is a phase 3 stage product being developed by Merck for Coronavirus Disease (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04939428. Target conditions include Coronavirus Disease (COVID-19).
What happened to similar drugs?
0 of 11 similar drugs in Coronavirus Disease (COVID-19) were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06667700 | Phase 3 | Recruiting |
| NCT04939428 | Phase 3 | Completed |
| NCT04575597 | Phase 2/3 | Completed |
| NCT04575584 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Coronavirus Disease (COVID-19)